Module 2 (GRWD5769 in combination with cemiplimab, administered IV) clinical trials

EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)

This study is testing a new drug, GRWD5769, for advanced cancers. It aims to help your immune system fight the cancer better, either alone or with another anti-cancer drug. Researchers want to see if it's safe and effective.